Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Nephrology
•
Onconephrology
•
Tumor Lysis Syndrome
Do you recommend testing for G6PD deficiency in those with whom rasburicase for tumor lysis syndrome is indicated?
Answer from: at Academic Institution
G6PD deficiency is a contraindication to the use of rasburicase and should be tested for prior to the use of this drug.
Sign in or Register to read more
Answer from: at Community Practice
You're supposed to test, but most do not. It's X-linked, so males are more susceptible. Certain populations are too: sub-Saharan Africa, the Mediterranean, and Southeast Asia.
Sign in or Register to read more
17203
17204
Related Questions
Would you recommend initiating RRT in a patient with tumor lysis syndrome and a phosphorus of 9 mg/dl or more who does not have symptomatic hypocalcemia or other indications for dialysis?
What factors should prompt a kidney biopsy to evaluate for monoclonal gammopathy of renal significance in a patient with MGUS and suspected chronic diabetic nephropathy?
Do you consider hyperuricemia as a potential etiology of an anion gap metabolic acidosis in patients with elevated uric acid levels and no other readily explainable causes of acidosis?
Do you recommend a kidney biopsy in a patient with myelodysplastic syndrome diagnosed two years prior who develops new onset proteinuria?
What are your next steps for managing biopsy-proven interstitial nephritis from checkpoint inhibitors in patients who do not have a response to prednisone?
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
What are your top takeaways from ASN 2023?
Do you recommend a kidney biopsy for patients who develop acute kidney injury after starting sacituzumab?
What are your management strategies for acute kidney injury attributed to pembrolizumab in patients with a kidney biopsy showing predominately acute tubular injury?
What is your approach to ESA use in patients with ESKD and active malignancy on treatment?